TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05189145

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: estradiol valerate
Description: 8mg orally on daily basis for 13 days beginning with the first day of either a spontaneously or induced menstrual cycle then assess by ultrasound

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estradiol valerate
Description: 8mg orally on daily basis for 13 days beginning with the first day of either a spontaneously or induced menstrual cycle then assess by ultrasound

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hormonal monitoring progesterone, estradiol, luteinizing hormone
Description: Serum Progesterone, estrogen \& LH measured on day 13 after priming endometrium with 8mg estradiol valerate on a daily basis beginning as early as the first day of menstrual cycle.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: transvaginal ultrasound examination
Description: Patients examined using transvaginal ultrasonography on day 13 of exogenous estrogen supplementation to measure endometrial thickness and to detect signs of escape ovulation

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: transvaginal ultrasound examination
Description: Patients examined using transvaginal ultrasonography on day 13 of exogenous estrogen supplementation to measure endometrial thickness and to detect signs of escape ovulation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone 400 Mg Vaginal Suppository
Description: Progesterone supplements given in form of daily two vaginal prontogest suppositories400 mg each

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone 400 Mg Vaginal Suppository
Description: Progesterone supplements given in form of daily two vaginal prontogest suppositories400 mg each

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hormonal monitoring progesterone and estradiol
Description: Measuring the serum Progesterone \& Estradiol in the early morning on the day of embryo transfer an progesterone supplementation adjusted as follows: Group II A: If P4 levels \< 5ng/dl, one 100 mg intramuscular injection daily added, Group II B: If P4 levels 5-10ng/dl, dydrogesterone three times daily added. Group II C: If P4 levels \>10ng, continued on 400 mg prontogest suppositories twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: group II A: 100 mg intramuscular injection daily Group II B: If P4 levels 5-10ng/dl dydrogesterone added
Study: NCT03216681

Intervention type: DRUG
Intervention: Hoat Huyet Nhat Nhat
Description: Administered orally twice a day, 2 tablets each time, for 45 days.

Intervention type: DRUG
Intervention: Tanakan 40mg
Description: Administered orally three times a day, 1 tablet each time, for 45 days.
Study: NCT02787785

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous Implantable Cardioverter Defibrillator
Description: The S-ICD is an entirely subcutaneous implantable cardioverter defibrillator.
Study: NCT03537222

Intervention type: DIAGNOSTIC_TEST
Intervention: Myeloma Patient Outcome Scale (MyPOS)
Description: Patients complete the MyPOS questionnaire on quality of life
Study: NCT02091804

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immediate Group
Description: The intervention consists of delivering the Promoting First Relationship (PFR) program. PFR comprises 10 sessions and lasts approximately 12 weeks. Each session lasts approximately 30 minutes, and begins with brief (\~10 min) discussions and education on the target topic for that week . The remaining 20 minutes will alternate between video recording a structured interaction between the caregiver and child or viewing the previous session's recording and engaging in reflective discussion about successful caregiving strategies and child's response to caregiver behavior. Trained PFR specialists who are community members use the 5 consultation strategies, labeled Joining, Positive Feedback, Instructive Feedback, Reflective Questions and Comments, and Instruction with Handouts.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wait-List group
Description: The intervention consists of delivering the Promoting First Relationship (PFR) program. PFR comprises 10 sessions and lasts approximately 12 weeks. Each session lasts approximately 30 minutes, and begins with brief (\~10 min) discussions and education on the target topic for that week . The remaining 20 minutes will alternate between video recording a structured interaction between the caregiver and child or viewing the previous session's recording and engaging in reflective discussion about successful caregiving strategies and child's response to caregiver behavior. Trained PFR specialists who are community members use the 5 consultation strategies, labeled Joining, Positive Feedback, Instructive Feedback, Reflective Questions and Comments, and Instruction with Handouts.
Study: NCT02973451

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Guided Bupivacaine
Description: Bupivacaine Laparoscopic GuidedTransversus Abdominis Plane Block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: local Bupivacaine
Description: Bupivacaine Trocar Site Infiltration
Study: NCT01839227

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurologic and neuropsychologic tests
Description: Cognitive functioning was assessed with the following test: Korean Mini-Mental State Examination (K-MMSE) and visuomotor test of D-LOTCA battery.~Regional cerebral oxygen saturation was continuously monitored using the INVOS 5100 (somatics,Troy, MI) with bifrontal placement of two sensors before the induction of the anesthesia until the end of operation.~Baseline rSO2 was defined as the average saturation value over a 1 min period before induction of general anesthesia, beginning approximately 3 min after the sensors were applied in supine position. After the induction, baseline prone rSO2 was defined over a 5min period after the change of position.~There is no intervention were made according to rSO2 values. Physiologic variables including BIS, PaCO2,PaO2, glucose, electrolyte, hematocrit, HR, MAP, and nasopharyngeal temperature were measured every 1 hours during the surgery.
Study: NCT03003728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elotuzumab
Description: Elotuzumab 10 mg/kg via intravenous infusion on days -16, -3, 12, and 26
Study: NCT02932631

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: THERAPY CONTROL AND MOVEMENT OF INDUCTION
Description: Volunteers conventional physiotherapy group will stretching, strengthening and / or mobilization and functional training of the affected muscles with 3 sets of 10 repetitions for 60 minutes.~The restriction therapy group and induction motion the volunteers will wear a brace on the top healthy member to be restricted in each session during the exercises for this group for a period of 60 minutes, encouraging tasks involving activities of daily living and / or daily. In group practice mental, the volunteers listen to a CD that in the first two minutes, will promote progressive relaxation where imaginary in a calm and quiet place followed by 13 minutes of listening to the restriction therapy exercise protocol and motion induction. The association group practices and mental restriction therapy, volunteer listens to the CD for 15 minutes following the same procedures mentioned in group practice mental, followed by exercises functional activities for 45 minutes in the paretic limb.
Study: NCT02897778

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of placebo-matching entinostat (containing inactive ingredients matching the appearance of the active product).
Study: NCT01144702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: artesunate & mefloquine combination
Description: A therapeutic trial of a single arm for prospective evaluation of responses of individuals with uncomplicated malaria by P. falciparum treated with combination artesunate + mefloquine for three days and monitored clinically and biochemically for 42 days.
Study: NCT03003728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan 200 mg/m2 Ivia intravenous infusion on day -3
Study: NCT04570332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BO-112 plus pembrolizumab
Description: Patients will be treated with the combination of BO-112 and pembrolizumab. Order of administration should be pembrolizumab then IT BO-112. BO-112 will be administered IT at a total dose of 1-2 mg at each administration to 1-8 tumor lesions using tuberculin (TB) syringes (or equivalent) with 20- to 25-gauge needles
Study: NCT03003728

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Stem Cell Transplant (ASCT)
Description: ASCT on day -2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Expanded Natural Killer (ENK) Cells
Description: ENK cell infusion on day 0
Study: NCT04570332

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tissue Biopsies
Description: Pre and post (if feasible) treatment tumor tissue biopsies will be used for correlative research.
Study: NCT03469700

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: general anesthesia
Description: Induction of general anesthesia will be performed followed by endotracheal intubation. General anesthesia is induced with 0.5-1 μg/kg fentanyl, 1.5-2 mg/kg propofol and 1-2 mg midazolam. Then, endotracheal intubation is facilitated by 0.15 mg/kg nimbex. Anesthesia is maintained by 1-1.5% sevoflurane, 0.5 μg/kg/h fentanyl, 0.6 mg/kg/h rocuronium, 60% nitrous oxide and 40% oxygen with Ultiva (Remifentanyl) 0.1-0.2 μg/kg/hr

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: general anesthesia
Description: Induction of general anesthesia will be performed followed by endotracheal intubation. General anesthesia is induced with 0.5-1 μg/kg fentanyl, 1.5-2 mg/kg propofol and 1-2 mg midazolam. Then, endotracheal intubation is facilitated by 0.15 mg/kg nimbex. Anesthesia is maintained by 1-1.5% sevoflurane, 0.5 μg/kg/h fentanyl, 0.6 mg/kg/h rocuronium, 60% nitrous oxide and 40% oxygen with Ultiva (Remifentanyl) 0.1-0.2 μg/kg/hr

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paravertebral block
Description: Bilateral paravertebral block guided by a nerve stimulator will be performed by injecting local anesthetic mixture from levels T11 to T6. Each 20 ml of the mixture will contain: 6 ml lidocaine 2%; 6 ml lidocaine 2% with adrenaline 5 μg /ml; 5 ml bupivacaine 0.5%; 50μg fentanyl (1 ml); and 2 ml saline 0.9%

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo PVB
Description: Placebo bilateral paravertebral block guided by a nerve stimulator will be performed by injecting normal saline from levels T11 to T6.
Study: NCT03749876

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Unfiltered Cigarettes
Description: Participants will be given unfiltered Pall Mall or Camel cigarettes to smoke for two weeks according to the brand they smoked prior to the start of the study. They will agree to smoke the cigarettes using a monitoring device (CReSS) that measures puffing behavior on five (5) days during each of the two weeks. They will also collect their cigarette butts on all days as a measure of smoking behaviors.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unfiltered Cigarettes
Description: Participants will be given unfiltered Pall Mall or Camel cigarettes to smoke for two weeks according to the brand they smoked prior to the start of the study. They will agree to smoke the cigarettes using a monitoring device (CReSS) that measures puffing behavior on five (5) days during each of the two weeks. They will also collect their cigarette butts on all days as a measure of smoking behaviors.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Filtered Cigarettes
Description: Participants will be given filtered Pall Mall or Camel cigarettes to smoke for two weeks according to the brand they smoked prior to the start of the study. They will agree to smoke the cigarettes using a monitoring device (CReSS) that measures puffing behavior on five (5) days during each of the two weeks. They will also collect their cigarette butts on all days as a measure of smoking behaviors.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Filtered Cigarettes
Description: Participants will be given filtered Pall Mall or Camel cigarettes to smoke for two weeks according to the brand they smoked prior to the start of the study. They will agree to smoke the cigarettes using a monitoring device (CReSS) that measures puffing behavior on five (5) days during each of the two weeks. They will also collect their cigarette butts on all days as a measure of smoking behaviors.
Study: NCT03359993

Intervention type: PROCEDURE
Intervention: Premedication of intubation
Description: The umbilical vein is punctured to inject drugs efficiently. The access is simple, the umbilical vein is clearly visible, and a blood reflux can be found easily. We used the same equipment required for a peripheral venous injection: 24 gauge cannula, antisepsis, compress, and a syringe with the prepared anesthetic drugs. We report 5 cases of intubations in the delivery room using this method to administer the premedication.
Study: NCT03845660

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic Alert
Description: Patients randomized to the intervention will have an alert of their prognosis based on the best available prognostic models for inpatient and 1-year mortality generated with information from their electronic health record, which will consist of a pop-up when the provider accesses a patient record to enter a progress note after the definitions for inclusions into the study have been registered.
Study: NCT03308890

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5mg Baraclude(entecavir)
Description: 0.5mg Baraclude (entecavir) QD for 6 months after cessation of TDF.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5mg Baraclude(entecavir)
Description: 0.5mg Baraclude (entecavir) QD for 12 month after cessation of TDF.
Study: NCT03807544

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Description: Transcutaneous electrical nerve stimulation
Study: NCT02284776

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic education
Description: People in hydrotherapeutic cure are following a program of Therapeutic Education. This program includes dietary advice, physical activities, behavior advice in order to change the lifestyle of the obese people.
Study: NCT04321746

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: ketamine will be administered at a dose of 0.3 mg/kg in normal saline at 0.9% (250 mL)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: the control group will receive only normal saline at 0.9%, with the same physical characteristics of the ketamine solution
Study: NCT02932631

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: THERAPY CONTROL AND MOVEMENT OF INDUCTION
Description: Volunteers conventional physiotherapy group will stretching, strengthening and / or mobilization and functional training of the affected muscles with 3 sets of 10 repetitions for 60 minutes.~The restriction therapy group and induction motion the volunteers will wear a brace on the top healthy member to be restricted in each session during the exercises for this group for a period of 60 minutes, encouraging tasks involving activities of daily living and / or daily. In group practice mental, the volunteers listen to a CD that in the first two minutes, will promote progressive relaxation where imaginary in a calm and quiet place followed by 13 minutes of listening to the restriction therapy exercise protocol and motion induction. The association group practices and mental restriction therapy, volunteer listens to the CD for 15 minutes following the same procedures mentioned in group practice mental, followed by exercises functional activities for 45 minutes in the paretic limb.
Study: NCT00751699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asacol
Description: Asacol tablets, 6 tablets per day at 7 am for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asacol
Description: Asacol tablets, 400 mg, 2 tablets at 7 am, 3 pm, and 11 pm for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lialda
Description: Lialda tablets 1.2 g, 2 tablets once a day at 7 am for 7 days
Study: NCT01156779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SR-exenatide
Description: Emulsion 0.5mg,1mg,2mg,4mg dosage (Dose-escalation) Single injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SR-exenatide
Description: Emulsion 0.5mg,1mg,2mg,4mg dosage (Dose-escalation) Single injection
Study: NCT03003728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALT-803
Description: ALT-803 (Interleukin-15 superagonist) 10 ug/kg via subcutaneous injection on days 1, 8, 15, and 22
Study: NCT02719015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rAd.CD40L
Description: Dose Escalation Phase Starting Dose: 5x10\^10 vp per tumor as an injection directly into 1-3 tumors every 3 weeks. Same tumors injected for each of the 4 injections at week 0, 3, 6 and 9. If the dose well tolerated, the rAd.CD40L escalated to 1x10\^11 vp. Subsequently enrolled patients injected at the same dose of 1x10\^11 vp. Number of injected sites/tumors increased to two sites/lesions if patients have \>/=2 injectable lesions, at the same injection dose of 1x10\^10 up to three separate sites/lesions if patients have \> 3 injectable lesions.~Dose Expansion Phase Starting Dose: MTD from Dose Escalation Phase.
Study: NCT03444662

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplement
Description: Cellulose and Sunflower oil

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Citicoline and Omega-3 supplement
Description: Citicoline and Omega-3

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 supplement
Description: Cellulose and Omega-3
Study: NCT03984864

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise therapy
Description: 3-4 items from a list of 10 general exercises - intended for treatment of low back pain

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise therapy
Description: 3-4 items from a list of 10 general exercises - intended for treatment of low back pain
Study: NCT03455088

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behavioral Group Therapy
Description: DBT is based on the model for the development of emotion regulation, designed for teaching how to regulate their adaptive emotions and behaviors cased by mood disorders , so it is valid for BN patient.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behavioral Group Therapy
Description: DBT is based on the model for the development of emotion regulation, designed for teaching how to regulate their adaptive emotions and behaviors cased by mood disorders , so it is valid for BN patient.
Study: NCT01462344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADVAIR 100/50mcg
Description: fluticasone propionate/salmeterol combination (100/50mcg) twice daily (AM and PM) for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADVAIR 250/50mcg
Description: fluticasone propionate/salmeterol combination (250/50mcg) twice daily (AM and PM) for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FLOVENT 100mcg
Description: fluticasone propionate (100) twice daily (AM and PM) for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FLOVENT 250mcg
Description: fluticasone propionate (250mcg) twice daily (AM and PM) for 6 months
Study: NCT01003249

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baclofen
Description: Subjects will be randomly assigned to placebo or baclofen groups. Daily dose will be doubled every three days, up to 80 mg or when side effects appear. At the end of 4 week drug will be tapered (halved every 2 days and quitted after 2 days of using 20 mg baclofen). After the 3 week washout period, questionnaires, diary, EMG and uroflowmetry will be repeated. Then patients initially assigned to the baclofen group will be assigned to the placebo group, and those assigned to the placebo group will be assigned to the baclofen group.~Patients would then receive a dose of baclofen 10 mg PO twice daily (or placebo twice daily), and then the dose will be escalated to 80 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Baclofen
Description: Subjects will be randomly assigned to placebo or baclofen groups. Daily dose will be doubled every three days, up to 80 mg or when side effects appear. At the end of 4 week drug will be tapered (halved every 2 days and quitted after 2 days of using 20 mg baclofen). After the 3 week washout period, questionnaires, diary, EMG and uroflowmetry will be repeated. Then patients initially assigned to the baclofen group will be assigned to the placebo group, and those assigned to the placebo group will be assigned to the baclofen group.~Patients would then receive a dose of baclofen 10 mg PO twice daily (or placebo twice daily), and then the dose will be escalated to 80 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Subjects will then randomly be assigned in placebo or baclofen groups. Daily dose will be doubled every three days, up to 80 mg or when side effects appear. At the end of 4 week drug will be tapered (halved every 2 days and quitted after 2 days of using 20 mg baclofen). After the 3 week washout period, questionnaires, diary, EMG and uroflowmetry will be repeated. Then patients initially assigned to the baclofen group will be assigned to the placebo group, and those assigned to the placebo group will be assigned to the baclofen group.~Patients would then receive a dose of baclofen 10 mg PO twice daily (or placebo twice daily), and then the dose will be escalated to 80 mg.
Study: NCT02719015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Dose Escalation and Expansion Phases: 2 mg/kg by vein every 3 weeks.
Study: NCT03660514

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Jovenes Sanos
Description: FP counselors in intervention clinics will a) provide counseling and education regarding risk of partner detection of FP methods, and women's and girls' strategies to use FP methods to minimize partner detection risk integrated into standard FP counseling, b) make brief inquiries to allow clients the opportunity to disclose experiences of RC and IPC (i.e., screening), c) provide method-specific counseling based on this information and the method chosen by the client, d) provide supported linkage of IPV survivors to local IPV support services (i.e. warm referral), and e) distribute palm-sized educational materials on RC and IPV, as well as IPV services.
Study: NCT02483260

Intervention type: DRUG
Group type: OTHER
Intervention: Ribavirin
Description: 1. Loading dose, 33 mg/kg (maximum dose: 2.64 g)~2. Followed in 6 hours by a dose of 16 mg/kg (maximum dose: 1.28 g) every 6 hours for the first 4 days (15 doses)~3. Followed by a dose of 8 mg/kg (maximum dose: 0.64 g) every 8 hours for the subsequent 6 days (18 doses).